ASX ANNOUNCEMENT **21 MARCH 2023**

POSITIVE PRE-IND MEETING WITH US FDA FOR NEW PHASE 1 CAR T STUDY

- Chimeric has received positive feedback and guidance from the US Food and Drug Administration (FDA) regarding its proposed Phase 1 clinical trial in gastrointestinal and neuroendocrine tumors with CHM 2101
- Significant milestone in the development pathway for CHM 2101, as the FDA advice supports Chimeric's planned Phase 1 clinical trial and technical operations strategy

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has successfully completed a pre-Investigational New Drug (pre-IND) meeting with the US Food and Drug Administration (FDA) and has received positive feedback on the development plan for CHM 2101. This is a significant milestone towards an Investigational New Drug (IND) Application and Phase 1 clinical trial for CHM 2101.

The objective of the meeting was to facilitate FDA regulatory communication and guidance through the IND submission process for CHM 2101. The pre-IND meeting package included details and specific questions regarding the clinical development plan and technical operations, including drug product manufacturing and quality release plan for CHM 2101.

The company received positive written responses from the FDA that provide a clear path to an IND submission for CHM 2101 and validates the team's efforts and accomplishments in preparing CHM 2101 for clinic.

"The positive feedback we received from the FDA was encouraging and aligns clearly with our development plan for CHM 2101," said Jennifer Chow, Chimeric's Chief Executive Officer and Managing Director. "We are highly appreciative of the FDA's support and guidance as this brings us closer to potentially transforming the lives of patients with gastrointestinal and neuroendocrine tumours."

CHM 2101 is a first in class, 3rd generation autologous CAR T cell therapy invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer, with the data demonstrating strong

evidence of efficacy with complete eradication of eight different types of gastrointestinal cancers with no relapse or toxicity. Chimeric is focused on advancing CHM 2101 towards a phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors
Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au